Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate
Merck IO Drug Extends Lead As Obesity Drugs Climb Table
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
